Detail page

Knowledge Web

Person

Olaf Witt (1965-)

Kinderarzt

Name	Olaf Witt
Time	1965- (Date of birth and death)
Place	Deutschland
Academic degree	Prof. Dr. med.
Profession	Kinderarzt (characteristic profession)
Related	Zentrum für Kinder- und Jugendmedizin (Heidelberg)
Further information	Leitender Oberarzt Pädiatrische Hämatologie und Onkologie, Leiter der Sektion Kindliche Hirntumore
Record type	Person
GND-Identifier	17275030X
Record ID	17275030X
Involved in show all LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Beyond germline genetic testing - heterozygous pathogenic variants in PMS2 in two children with osteosarcoma and ependymoma Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome Deficiencies of paediatric oncology phase I/II protocol regulatory submissions in Germany Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types Doubling Recruitment of Pediatric Low-grade Glioma within Two Decades does not change Outcome – Report from the German LGG Studies A study of regulatory challenges of paediatric oncology phase I/II trial submissions and guidance on protocol development Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach Favorable prognosis in pediatric brainstem low‐grade glioma: report from the German SIOP‐LGG 2004 cohort Natural history of pediatric low-grade glioma disease - first multi-state model analysis Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines Author Correction: The landscape of genomic alterations across childhood cancers A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment The landscape of genomic alterations across childhood cancers Evaluierung des Sirtuinisoenzym-Expressionsmusters in kindlicher akuter lymphoblastischer Leukämie The whole-genome landscape of medulloblastoma subtypes Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets HDAC8 : : a multifaceted target for therapeutic interventions Adaptive designs with arbitrary dependence structure Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer Dissecting the genomic complexity underlying medulloblastoma A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes Untersuchungen über Endocytoserezeptor-Proteine eines kleinen Dermatansulfat-Proteoglykans (Decorin) in menschlichen Keratinocyten

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Olaf Witt (1965-)

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells

Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Beyond germline genetic testing - heterozygous pathogenic variants in PMS2 in two children with osteosarcoma and ependymoma

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

Deficiencies of paediatric oncology phase I/II protocol regulatory submissions in Germany

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

Local and systemic therapy of recurrent medulloblastomas in children and adolescents: results of the P-HIT-REZ 2005 study

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Doubling Recruitment of Pediatric Low-grade Glioma within Two Decades does not change Outcome – Report from the German LGG Studies

A study of regulatory challenges of paediatric oncology phase I/II trial submissions and guidance on protocol development

Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study

Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions—A calibration approach

Favorable prognosis in pediatric brainstem low‐grade glioma: report from the German SIOP‐LGG 2004 cohort

Natural history of pediatric low-grade glioma disease - first multi-state model analysis

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance

Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience

The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines

Author Correction: The landscape of genomic alterations across childhood cancers

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

The landscape of genomic alterations across childhood cancers

Evaluierung des Sirtuinisoenzym-Expressionsmusters in kindlicher akuter lymphoblastischer Leukämie

The whole-genome landscape of medulloblastoma subtypes

Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients

MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells

Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets

HDAC8 : : a multifaceted target for therapeutic interventions

Adaptive designs with arbitrary dependence structure

Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

Dissecting the genomic complexity underlying medulloblastoma

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept

Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes

Untersuchungen über Endocytoserezeptor-Proteine eines kleinen Dermatansulfat-Proteoglykans (Decorin) in menschlichen Keratinocyten